Mustapha El Lakis1, Pavel Nockel1, Apostolos Gaitanidis2, Bin Guan3, Sunita Agarwal3, James Welch3, William F Simonds3, Lee Weinstein3, Stephen Marx3, Naris Nilubol1, Dhaval Patel1, Roxanne Merkel1, Amit Tirosh4, Electron Kebebew5. 1. Endocrine Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD. 2. Endocrine Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD; Department of Surgery, Democritus University of Thrace Medical School, Alexandroupoli, Greece. 3. Metabolic Disease Branch, National Institutes of Digestive Disease and Kidney, National Institutes of Health, Bethesda, MD. 4. Endocrine Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD; Sackler Faculty of Medicine, Tel Aviv University, Israel. 5. Endocrine Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD; Department of Surgery, The George Washington University, School of Medicine and Health Sciences, Washington, DC. Electronic address: kebebewe@mail.nih.gov.
Abstract
BACKGROUND: Approximately 10% of patients with primary hyperparathyroidism (PHPT) have hereditary disease. Hereditary PHPT may be syndromic (MEN1, 2, and 4 and hyperparathyroidism-jaw tumor syndrome) or non-syndromic (familial isolated PHPT). There are limited data on the probability of testing positive for genetic mutation based on clinical presentation. The aim of this study was to determine potential associations between clinical and biochemical features and mutation in susceptibility genes for PHPT in patients with a family history of PHPT. STUDY DESIGN: A retrospective analysis of 657 patients who had an initial parathyroidectomy for PHPT at a tertiary referral center. Logistic regression analyses were performed in 205 patients with a family history of PHPT to identify factors associated with a positive genetic test. RESULTS: Of 657 patients, 205 (31.2%) had a family history of PHPT. Of those 205 patients, 123 (60%) had a germline mutation detected (91 MEN1, 14 CDC73, and 18 GCM2). In univariate analysis, younger age (45 years and younger), male sex, multigland disease, and parathyroid carcinoma were associated with positive germline mutation; biochemical cure after an initial parathyroidectomy was less frequent in patients with familial PHPT (96.2% vs 89.2%; p = 0.005). In multivariable analysis, age 45 years and younger, male sex, and multigland disease were independent factors associated with positive genetic testing. CONCLUSIONS: In addition to a family history of PHPT, male sex, age 45 years and younger, and presence of multigland disease, should prompt physicians to offer the opportunity for genetic counseling and testing, as it could influence the management of patients with PHPT. Published by Elsevier Inc.
BACKGROUND: Approximately 10% of patients with primary hyperparathyroidism (PHPT) have hereditary disease. Hereditary PHPT may be syndromic (MEN1, 2, and 4 and hyperparathyroidism-jaw tumor syndrome) or non-syndromic (familial isolated PHPT). There are limited data on the probability of testing positive for genetic mutation based on clinical presentation. The aim of this study was to determine potential associations between clinical and biochemical features and mutation in susceptibility genes for PHPT in patients with a family history of PHPT. STUDY DESIGN: A retrospective analysis of 657 patients who had an initial parathyroidectomy for PHPT at a tertiary referral center. Logistic regression analyses were performed in 205 patients with a family history of PHPT to identify factors associated with a positive genetic test. RESULTS: Of 657 patients, 205 (31.2%) had a family history of PHPT. Of those 205 patients, 123 (60%) had a germline mutation detected (91 MEN1, 14 CDC73, and 18 GCM2). In univariate analysis, younger age (45 years and younger), male sex, multigland disease, and parathyroid carcinoma were associated with positive germline mutation; biochemical cure after an initial parathyroidectomy was less frequent in patients with familial PHPT (96.2% vs 89.2%; p = 0.005). In multivariable analysis, age 45 years and younger, male sex, and multigland disease were independent factors associated with positive genetic testing. CONCLUSIONS: In addition to a family history of PHPT, male sex, age 45 years and younger, and presence of multigland disease, should prompt physicians to offer the opportunity for genetic counseling and testing, as it could influence the management of patients with PHPT. Published by Elsevier Inc.
Authors: I Schuffenecker; M Virally-Monod; R Brohet; D Goldgar; B Conte-Devolx; L Leclerc; O Chabre; A Boneu; J Caron; C Houdent; E Modigliani; V Rohmer; M Schlumberger; C Eng; P J Guillausseau; G M Lenoir Journal: J Clin Endocrinol Metab Date: 1998-02 Impact factor: 5.958
Authors: Bin Guan; James M Welch; Julie C Sapp; Hua Ling; Yulong Li; Jennifer J Johnston; Electron Kebebew; Leslie G Biesecker; William F Simonds; Stephen J Marx; Sunita K Agarwal Journal: Am J Hum Genet Date: 2016-10-13 Impact factor: 11.025
Authors: Lee F Starker; Tobias Akerström; William D Long; Alberto Delgado-Verdugo; Patricia Donovan; Robert Udelsman; Richard P Lifton; Tobias Carling Journal: Horm Cancer Date: 2012-04 Impact factor: 3.869
Authors: Scott M Wilhelm; Tracy S Wang; Daniel T Ruan; James A Lee; Sylvia L Asa; Quan-Yang Duh; Gerard M Doherty; Miguel F Herrera; Janice L Pasieka; Nancy D Perrier; Shonni J Silverberg; Carmen C Solórzano; Cord Sturgeon; Mitchell E Tublin; Robert Udelsman; Sally E Carty Journal: JAMA Surg Date: 2016-10-01 Impact factor: 14.766
Authors: Ewa Lundgren; Emil G Hagström; Jonas Lundin; Kajsa Winnerbäck; Johanna Roos; Sverker Ljunghall; Jonas Rastad Journal: World J Surg Date: 2002-06-06 Impact factor: 3.352
Authors: Xavier M Keutgen; Naris Nilubol; Sunita Agarwal; James Welch; Craig Cochran; Steve J Marx; Lee S Weinstein; William F Simonds; Electron Kebebew Journal: Ann Surg Oncol Date: 2016-07-27 Impact factor: 5.344
Authors: Sunita M C De Sousa; Richard W Carroll; Alex Henderson; John Burgess; Roderick J Clifton-Bligh Journal: Endocrine Date: 2021-11-13 Impact factor: 3.633
Authors: Shafaq Khairi; Jenae Osborne; Michelle F Jacobs; Gregory T Clines; Barbra S Miller; David T Hughes; Tobias Else Journal: Horm Cancer Date: 2020-08-05 Impact factor: 3.869